Debiopharm Joins Discussions With International Health Organisations to Fight Anti-Microbial Resistance at the 2023 World AMR Congress
6.9.2023 15:00:00 EEST | Business Wire | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced their participation in the keynote panel and antibiotic development track sessions at the 2023 World AMR conference from September 7th – 8th, 2023.
Debiopharm’s panelist Morgane Vanbiervliet, Market Intelligence & Business Development Manager, Infectious Diseases, is part of the AMR preparedness keynote panel to be moderated by Bruce Y. Lee from Forbes and involving representatives from the CDC, Menarini Group, IFPMA and the AMR Action Fund. A further Debiopharm-sponsored breakout session, moderated by Dr. Ricardo Chaves, Executive Medical Director, will feature Dr. L. Clifford McDonald, Associate Director for Science in the Division of Healthcare Quality Promotion at the CDC, explaining the relevance of novel microbiome-sparing antibiotics in combating AMR, and the potential need for new regulatory approval and reimbursement pathways.*
“It’s important to harness these open dialogues between public organizations and the infectious disease industry experts at World AMR to produce action that can prepare us to face the emerging wave of resistant infections,” explained Morgane Vanbiervliet, Market Intelligence & Business Development Manager, Infectious Diseases, Debiopharm. “We know that uncontrollable infectious diseases are everybody’s business, and that our preparation efforts must involve the reinforcement of prevention measures, better stewardship education, and sustainable market pathways for new effective treatments.”
“The CDC recognizes the importance of the human microbiome as it provides key resistance to human colonization with multidrug-resistant pathogens. Along with products that will reduce the degree of colonization (i.e. pathogen reduction), or drugs that will restore the microbiome, we need therapeutic antibiotics that spare the microbiome, by being highly-selective for only specific pathogens.” expressed Dr. L. Clifford McDonald, Associate Director for Science in the Division of Healthcare Quality Promotion, CDC.
Last year’s special report from the CDC on the impact of COVID-19 on antimicrobial resistance revealed that 6 of the 18 most alarming bacterial menaces cost the US more that $4.6 billion each year and thousands of human lives.4 The agency’s 18 bacterial and fungal threats include 2 pathogens for which Debiopharm is currently developing new antibiotics: Neisseria gonorrhoeae and methicillin-resistant Staphylococcus aureus. Debiopharm’s FabI inhibitor therapies are part of a new pathogen-specific antibiotic class that is being researched for its capacity to effectively treat a single type of bacteria and thereby preserve the microbiome and avoid subsequent spread of AMR.
|
World AMR 2023 Session details |
Congress agenda |
Speakers |
|
Keynote panel Sept. 7th 08:35 EST
|
How can we push AMR to the forefront of preparedness? |
Morgane Vanbiervliet, Market Intelligence & Business Development Manager, Infectious Diseases, Debiopharm + other invited speakers
|
|
Panel discussion Sept. 7th 11:00–11:30 EST
|
Antibiotic Development stream
The public health case for microbiome-sparing antibiotics: Potential need for new pathways in regulatory approval and reimbursement
|
Moderator:
Executive Medical Director Debiopharm
Speaker: Dr.L. Clifford McDonald, Associate Director for Science in the Division of Healthcare Quality Promotion, CDC
|
About afabicin
Afabicin (Debio 1450) is Debiopharm’s first-in-class FabI inhibitor against Staphylococcus spp., whose methicillin-resistant Staphylococcus aureus (MRSA) strains are high on the WHO global priority pathogen list and deemed a “serious threat” by the CDC. Afabicin can be administered orally or IV and selectively targets Staphylococcus ’ essential bacterial fatty acid biosynthesis. Promising results have been obtained in a comparative double-blind Phase 2 trial with afabicin in acute bacterial skin and skin structure infections. Currently, a Phase 2 trial in bone and joint infections is being conducted in several countries comparing afabicin to standard antibiotics.
About Debio 1453
Analogous to afabicin, the preclinical compound Debio 1453 is a potential first in class pathogen-specific drug targeting the essential bacterial fatty acid biosynthesis pathway. Debio 1453 is administered orally to treat Neisseria gonorrhoeae , the bacteria causing the sexually transmitted disease gonorrhea, a cause of serious and permanent health issues including infertility, ectopic pregnancy, cardiovascular and neurological problems.
Debiopharm’s fight against antimicrobial resistance
Debiopharm, an innovation-focused, Swiss biopharmaceutical company is one of the few privately owned companies developing novel class antibiotics to combat hard-to-treat infections. Through their unique partnership-based business model, the company is advancing pathogen-specific antibiotics from early stage through phase II clinical research with afabicin, specifically targeting staphylococci, being the most clinically advanced for the treatment of bone and joint infections. As a result of high selectivity, FabI inhibitors specifically target selected pathogens while preserving intestinal microbiota and meet all four WHO 2020 innovation criteria: new chemical class, new target, new mode of action and no cross-resistance to other antibiotic classes.
For more information, please visit www.debiopharm.com
We are on Twitter. Follow us @DebiopharmNews at http://twitter.com/DebiopharmNews
References
[1] Morrison L, Zembower TR. Antimicrobial resistance. Gastrointest Endosc Clin N Am. 2020 Oct;30(4):619-635.
[2] Antimicrobial resistance surveillance in Europe 2023–2021 data. www.who.int/europe/publications/i/item/9789289058537
[3] CDC Antibiotic resistance threats in the United States, 2019. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
[4] COVID-19 U.S. Impact on Antimicrobial Resistance. https://www.cdc.gov/drugresistance/pdf/covid19-impact-report-508.pdf
Disclosures
* Speaker disclosures: Dr. McDonald has no relevant financial or non-financial relationships to disclose. The findings and conclusions of this presentation are those of the author and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the U.S. Department of Health and Human Services. Any use of trade names and commercial sources is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention or the U.S. Department of Health and Human Services.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230906072351/en/
Contact information
Debiopharm Contact
Dawn Bonine
Head of Communication
dawn.bonine@debiopharm.com
Tel: +41 (0)21 321 01 11
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wolters Kluwer’s Future Ready Accountant report: Redesigning work around AI is the next competitive advantage18.11.2026 07:00:00 EET | Press release
Wolters Kluwer Tax & Accounting today released the third edition of its Future Ready Accountant report, revealing a profession operating from a position of strength but at a turning point. Based on responses from more than 2,600 accounting professionals worldwide, the report finds firms are growing, confident, and widely adopting AI. However, few have redesigned how information, workflows, and professional expertise work together. The report shows that this transformation is what will turn today’s growth into lasting value. “Adopting AI is only the first step. The real advantage comes from connecting it to how the whole firm works,” said Jason Marx, CEO, Wolters Kluwer Tax & Accounting. “This year’s Future Ready Accountant report shows the firms that pull ahead will be the ones that rethink their workflows and give their people more room to create value for clients.” The global report features exclusive editions for the U.S., Canada, Europe, and APAC markets, offering region-specific i
Visa Expands Agentic Ready to Help Scale Trusted AI Commerce Globally18.11.2026 06:30:00 EET | Press release
Visa (NYSE: V), a world leader in digital payments, today announced the expansion of the Visa Agentic Ready program to the acceptance ecosystem. As a part of Visa Intelligent Commerce, the expanded program helps merchants, payment service providers (PSPs), and acquirers prepare for agent-initiated transactions and participate in the next era of commerce. The program is launching with more than 140 participants, with additional financial institutions, merchants and enablers expected to join throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117269823/en/ "Agentic commerce is already taking shape, but scaling it requires more than innovation. Merchants need confidence in who they're transacting with, and payment providers need to know these transactions can move securely and reliably through existing infrastructure," said Rubail Birwadker, SVP, Growth Products & Partnerships, Visa. "No one company can solve tha
Venture Global and China Gas Announce Increased Long-Term LNG Agreement18.11.2026 02:00:00 EET | Press release
Today, Venture Global, Inc. (“Venture Global”; NYSE: VG) and China Gas Holdings Limited (“China Gas”; stock code: 0384.HK), a leading natural gas operator in China, announced the execution of an increased Sales and Purchase Agreement (SPA) for the total purchase of 1.0 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030. This agreement upsizes the previous SPA announced by the two parties in September 2026 for the purchase of 0.5 MTPA by another newly-agreed 0.5 MTPA. Venture Global’s total current long-term offtake with China Gas is now 3.0 MTPA under 20-year SPAs supplied across Venture Global’s portfolio. "Venture Global is pleased to continue growing our LNG partnership with China Gas, a leading natural gas operator in China, and help meet the country's growing energy needs with reliable, low-cost American LNG from across our Louisiana projects,” said Venture Global CEO Mike Sabel. "We are pleased to further expa
UPS Announces Agreement to Acquire Smartways Logistics17.11.2026 23:00:00 EET | Press release
UPS (NYSE: UPS) today announced it has entered into an agreement to acquire Smartways Logistics (Smartways), a healthcare logistics provider serving Australia and New Zealand. Once completed, the acquisition will enhance UPS Healthcare’s time-critical transportation capabilities in the region. Smartways enables healthcare customers to move critical shipments quickly and reliably, with specialized services for life sciences, medical devices, clinical trials and radiopharmaceuticals. The acquisition will build on UPS Healthcare’s ability to deliver for customers with urgent and complex logistics needs, while expanding the services available in Australia, New Zealand and the Asia Pacific region. “As healthcare becomes increasingly complex, logistics plays an even more critical role. It takes specialized capabilities and precision at every step to help vital healthcare products reach patients safely, reliably and when they’re needed,” said Wilfredo Ramos, UPS EVP and Chief International, H
Spatial Announces Release 2027 1.0 with New Enhancements Across CAD Modeling, Interoperability, Data Preparation, and Meshing17.11.2026 21:10:00 EET | Press release
Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced the availability of its 2027 1.0 Release. This latest release introduces new capabilities and enhancements across Spatial's 3D ACIS Modeler, CGM Modeler, 3D InterOp, Data Prep and CSM/CVM product lines. Designed to improve efficiency, flexibility and robustness across CAD modeling, interoperability, data preparation and simulation workflows, the release delivers enhanced geometry processing, expanded modeling capabilities, improved CAD translation and advances in mesh generation for a better workflow coverage. 3D ACIS Modeler Enhanced Blending (Filleting) The 3D ACIS Modeler introduces support for asymmetric fixed-width blends with a conic cross-section, providing users with finer control over smooth transitions between edges. This enhancement builds on the symmetric fixed-width blend with a conic cross-section capabilit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
